# VEGF and TKI Kidney Toxicity: Pressure, Protein, Microvasculature

Monitor whether the renal and vascular abnormalities improve and whether treatment can continue safely. Persistent injury may need additional evaluation.

![Infographic: VEGF and TKI Kidney Toxicity: Pressure, Protein, Microvasculature](https://urinenephrology.org/visual-reference/images/mastery-vegf.png?v=20261003c)

## Targeted cancer therapy has renal targets too

VEGF-pathway inhibition can affect vascular regulation and glomerular integrity. Tyrosine kinase inhibitors vary in selectivity and adverse effects.

## Watch for new signals

Rising blood pressure, increasing proteinuria, edema, or reduced kidney function can indicate treatment-related injury.

## Look for renal microvascular injury

Record BP and quantify proteinuria; review creatinine, platelets, hemolysis markers, and sediment when TMA is suspected. Kidney-limited TMA may lack striking systemic hemolysis. New major proteinuria or declining filtration should not be dismissed as simply an expected BP effect.

## Match intervention to severity

A manageable BP rise may permit continued cancer therapy with treatment and monitoring. Severe hypertension, nephrotic protein loss, or suspected TMA may require interruption, biopsy, or a regimen change coordinated with oncology. Apply the individual drug’s hold rules; there is no universal VEGF/TKI threshold covering every agent.

## Avoid a class-wide assumption

A mild pressure rise and a thrombotic microangiopathy are different clinical problems. Agent-specific evidence and cancer benefit matter.

## Follow after intervention

Monitor whether the renal and vascular abnormalities improve and whether treatment can continue safely. Persistent injury may need additional evaluation.

## Source lessons

- [vegf tki nephrotoxicity review](https://urinenephrology.org/mastery/onconephrology/vegf-tki-nephrotoxicity-review.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.